​

Black Diamond Therapeutics (BDTX) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

BDTX Stock Forecast

Black Diamond Therapeutics (BDTX) stock forecast, based on 9 Wall Street analysts, predicts a 12-month average price target of $14.75, with a high of $20.00 and a low of $11.00. This represents a 984.56% increase from the last price of $1.36.

- $4 $8 $12 $16 $20 High: $20 Avg: $14.75 Low: $11 Last Closed Price: $1.36

BDTX Stock Rating

Black Diamond Therapeutics stock's rating consensus is Buy, based on 9 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 9 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 9 0 9 Strong Sell Sell Hold Buy Strong Buy

BDTX Price Target Upside V Benchmarks

TypeNameUpside
StockBlack Diamond Therapeutics984.56%
SectorHealthcare Stocks 33.91%
IndustryBiotech Stocks 83.49%

Price Target Trends

1M3M12M
# Anlaysts--3
Avg Price Target--$14.33
Last Closing Price$1.36$1.36$1.36
Upside/Downside--953.68%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 2524---6
Mar, 2534---7
Feb, 2534---7
Jan, 2534---7
Dec, 2434---7
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jul 31, 2024Laura PrendergastRaymond James$20.00$5.91238.41%1370.59%
Jun 03, 2024Joseph CalanzaroPiper Sandler$12.00$4.78151.05%782.35%
May 16, 2024Robert BurnsH.C. Wainwright$11.00$5.44102.21%708.82%
Apr 08, 2024Robert DriscollWedbush$16.00$5.06216.21%1076.47%
Mar 18, 2024Raghuram SelvarajuH.C. Wainwright$12.00$4.70155.32%782.35%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 23, 2024Cowen & Co.BuyBuyhold
Sep 18, 2024H.C. WainwrightBuyBuyhold
Sep 10, 2024Piper SandlerOverweightOverweighthold
Jul 30, 2024Raymond JamesOutperforminitialise
Jun 03, 2024Piper SandlerOverweightOverweighthold
May 16, 2024H.C. WainwrightBuyBuyhold
Apr 08, 2024WedbushOutperformOutperformhold
Jun 28, 2023H.C. WainwrightBuyupgrade
Jun 27, 2023WedbushOutperformupgrade

Financial Forecast

EPS Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.88$-1.27----
Avg Forecast$-1.98$-1.30$-1.22$-1.51$-1.73$-1.12
High Forecast$-1.95$-1.24$-0.82$-0.77$-0.72$-1.12
Low Forecast$-2.02$-1.34$-1.93$-2.47$-3.11$-1.12
Surprise %-5.05%-2.31%----

Revenue Forecast

$0 $30M $60M $90M $120M $150M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast--$438.00K$3.89M$14.87M$107.50M
High Forecast--$438.00K$3.89M$14.87M$107.50M
Low Forecast--$438.00K$3.89M$14.87M$107.50M
Surprise %------

Net Income Forecast

$-150M $-120M $-90M $-60M $-30M $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-82.44M$-69.68M----
Avg Forecast$-87.43M$-56.70M$-81.55M$-71.21M$-84.22M$-49.34M
High Forecast$-85.88M$-54.50M$-36.13M$-33.85M$-31.66M$-49.34M
Low Forecast$-88.97M$-58.90M$-85.03M$-108.57M$-136.77M$-49.34M
Surprise %-5.70%22.88%----

BDTX Forecast FAQ

Is Black Diamond Therapeutics stock a buy?

Black Diamond Therapeutics stock has a consensus rating of Buy, based on 9 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 9 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Black Diamond Therapeutics is a favorable investment for most analysts.

What is Black Diamond Therapeutics's price target?

Black Diamond Therapeutics's price target, set by 9 Wall Street analysts, averages $14.75 over the next 12 months. The price target range spans from $11 at the low end to $20 at the high end, suggesting a potential 984.56% change from the previous closing price of $1.36.

How does Black Diamond Therapeutics stock forecast compare to its benchmarks?

Black Diamond Therapeutics's stock forecast shows a 984.56% upside, outperforming the average forecast for the healthcare stocks sector (33.91%) and outperforming the biotech stocks industry (83.49%).

What is the breakdown of analyst ratings for Black Diamond Therapeutics over the past three months?

  • April 2025: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 42.86% Strong Buy, 57.14% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 42.86% Strong Buy, 57.14% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Black Diamond Therapeutics’s EPS forecast?

Black Diamond Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.22, marking a -3.94% decrease from the reported $-1.27 in 2024. Estimates for the following years are $-1.51 in 2026, $-1.73 in 2027, and $-1.12 in 2028.

What is Black Diamond Therapeutics’s revenue forecast?

Black Diamond Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $438K, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $3.89M, followed by $14.87M for 2027, and $107.5M for 2028.

What is Black Diamond Therapeutics’s net income forecast?

Black Diamond Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-81.551M, representing an 17.04% increase from the reported $-69.676M in 2024. Projections indicate $-71.207M in 2026, $-84.216M in 2027, and $-49.341M in 2028.